Stem definition | Drug id | CAS RN |
---|---|---|
antibacterials, nalidixic acid derivatives | 1013 | 74011-58-8 |
Dose | Unit | Route |
---|---|---|
0.80 | g | O |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 4 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 0.60 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 45 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 62.44 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 87 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Vd (Volume of distribution) | 2 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 5.40 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.80 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 5.10 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
Dec. 31, 1991 | FDA |
None
None
None
None
Source | Code | Description |
---|---|---|
ATC | J01MA04 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE QUINOLONE ANTIBACTERIALS Fluoroquinolones |
CHEBI has role | CHEBI:36047 | antibacterial drugs |
CHEBI has role | CHEBI:59517 | DNA synthesis inhibitors |
MeSH PA | D000900 | Anti-Bacterial Agents |
MeSH PA | D000890 | Anti-Infective Agents |
MeSH PA | D000970 | Antineoplastic Agents |
MeSH PA | D065609 | Cytochrome P-450 CYP1A2 Inhibitors |
MeSH PA | D065607 | Cytochrome P-450 Enzyme Inhibitors |
MeSH PA | D004791 | Enzyme Inhibitors |
MeSH PA | D065606 | Metabolic Side Effects of Drugs and Substances |
MeSH PA | D059005 | Topoisomerase II Inhibitors |
MeSH PA | D059003 | Topoisomerase Inhibitors |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Gonorrhea | indication | 15628003 | DOID:7551 |
Acute gonococcal cervicitis | indication | 20943002 | DOID:10615 |
Acute gonococcal urethritis | indication | 29864006 | |
Gonorrhea of rectum | indication | 42746002 | |
Urinary tract infectious disease | indication | 68566005 | |
Gonorrhea of pharynx | indication | 74372003 | |
Chancroid | off-label use | 266143009 | DOID:13778 |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 6.14 | acidic |
pKa2 | 8.63 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
V-type proton ATPase subunit B, brain isoform | Enzyme | IC50 | 5 | CHEMBL | |||||
RISC-loading complex subunit TARBP2 | Unclassified | Kd | 7.03 | CHEMBL | |||||
Topoisomerase IV | Enzyme | INHIBITOR | CHEMBL | CHEMBL | |||||
DNA gyrase | Enzyme | INHIBITOR | CHEMBL | CHEMBL | |||||
DNA gyrase subunit A | Enzyme | WOMBAT-PK |
ID | Source |
---|---|
4020144 | VUID |
N0000148115 | NUI |
D00310 | KEGG_DRUG |
4020144 | VANDF |
C0014310 | UMLSCUI |
CHEBI:157175 | CHEBI |
CHEMBL826 | ChEMBL_ID |
DB00467 | DRUGBANK_ID |
D015365 | MESH_DESCRIPTOR_UI |
3229 | PUBCHEM_CID |
8882 | IUPHAR_LIGAND_ID |
5351 | INN_ID |
325OGW249P | UNII |
3925 | RXNORM |
4658 | MMSL |
d00099 | MMSL |
003660 | NDDF |
387550004 | SNOMEDCT_US |
96084004 | SNOMEDCT_US |
None